ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis (Q34706896)

4 August 2017

ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis (English)

1 reference

4 August 2017

1 reference

F Révillion

1

1 reference

4 August 2017

V Lhotellier

2

1 reference

4 August 2017

L Hornez

3

1 reference

4 August 2017

J Bonneterre

4

1 reference

4 August 2017

J-P Peyrat

5

1 reference

4 August 2017

24 October 2007

1 reference

4 August 2017

1 reference

4 August 2017

19

1 reference

4 August 2017

73-80

1 reference

4 August 2017

1

1 reference

Oncogenic growth factor receptors: implications for signal transduction therapy

4 August 2017

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM431

The role of erbB-2 and its ligands in growth control of malignant breast epithelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM431

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM431

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM431

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM431

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM431

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM431

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM431

Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM431

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM431

TGFalpha expression impairs Trastuzumab-induced HER2 downregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM431

Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM431

Co-Expression of ErbB-Family Members in Human Breast Cancer: Her-2/neu is the Preferred Dimerization Candidate in Nodal-positive Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM431

Co-expression of neuregulins 1, 2, 3 and 4 in human breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM431

The evolution of gene regulation by transcription factors and microRNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM431

Expression of transforming growth factor alpha (TGF alpha) in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM431

Cloning and expression of cDNA encoding human betacellulin, a new member of the EGF family

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM431

Heparin-binding EGF-like growth factor is present in human amniotic fluid and breast milk

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM431

Expression of amphiregulin and epidermal growth factor receptor in human breast cancer: analysis of autocriny and stromal-epithelial interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM431

Expression of messenger RNA for amphiregulin, heregulin, and cripto-1, three new members of the epidermal growth factor family, in human breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDM431

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDM431

1 reference

4 August 2017

1 reference